Department of Veterans Affairs researchers are launching what they describe as the largest study yet examining whether semaglutide medications can help veterans struggling with alcohol addiction. The results could eventually push federal regulators to approve the popular GLP 1 drugs as a broadly available treatment for alcohol use disorder.

The effort is called the Cessation or Reduction of Alcohol Consumption in Veterans trial. Dr. David Oslin, the study’s lead researcher, said the project is intended to produce more “definitive” evidence and determine whether semaglutide could become a “more palatable” option for patients and physicians.

Semaglutide imitates the naturally occurring GLP 1 hormone in the human body. Initially developed as a diabetes medication, it has become widely known through weight loss drugs such as Ozempic and Wegovy.

Researchers believe that familiarity could help move alcohol addiction treatment beyond specialized psychiatric and addiction clinics. Instead, veterans might eventually obtain the medication through the primary care providers they already know and trust.

Here's What They're Not Telling You About Your Retirement

“It really opens the door to being more of a front-line drug that could be available, say, in primary care or other settings where patients are very comfortable going,” Oslin said. “Primary care is our frontline mental health program. It’s where mental health starts for almost all patients, whether that be for addiction, depression, anxiety, whatever. We need better tools that those providers could potentially use and get more people in treatment.”

More than 400,000 veterans have received an alcohol use disorder diagnosis, yet fewer than 40,000 are receiving medication for it. Oslin called those treatment rates “too low,” although they remain higher than the medication treatment rate among the broader American population.

Current options include counseling, formal addiction programs, Naltrexone and Topiramate. However, Oslin said “the reality is, all those treatments are woefully underused both by clinicians as well as patients,” leaving a major gap between diagnosis and meaningful medical care.

The new trial will enroll more than 600 veterans diagnosed with moderate to severe alcohol use disorder. Participants will administer weekly doses of either semaglutide or a placebo while researchers track cravings, drinking behavior, addiction symptoms and changes in physical and mental health.

This Could Be the Most Important Video Gun Owners Watch All Year

The study was deliberately designed around primary care rather than mandatory psychiatric treatment. Local VA clinicians will conduct brief medical management appointments lasting roughly 15 to 20 minutes, an approach Oslin described as “therapy lite,” while helping veterans establish goals related to alcohol consumption.

“Requiring people to be in a psychiatric clinic or to be in an addiction clinic, we actually didn’t want to do that because that makes it much more complicated to make the results more available to people,” Oslin said. That practical design could make the findings more useful in everyday medical settings, rather than limiting them to specialized programs.

Dr. Eric Dieperink, the psychiatrist leading the Minneapolis VA portion of the trial, said participants should prepare for a “fairly large initial commitment.” Veterans will undergo detailed medical evaluations, repeated blood testing and assessments to establish an appropriate dosage, which may gradually increase during the study.

The research is not starting from scratch. Three previous studies found that semaglutide reduced drinking behavior among patients with alcohol use disorder, producing “robust therapeutic effects,” fewer “heavy drinking days” and reductions in the number of drinks consumed each day.

“GLP-1s are naturally occurring peptides in all of us, and these medications sort of mimic that natural process and seem to dampen people’s desire for excessive activities like excessive eating or excessive alcohol intake,” Oslin said. Researchers now want to determine whether that effect holds up across a much larger veteran population.

With more than 600 planned participants, the VA project is nearly “six times” larger than some earlier trials. That scale is intentional because researchers hope to “provide definitive evidence” strong enough for the Food and Drug Administration to consider a “label change.”

Such a change would permit semaglutide to be officially prescribed and marketed as a treatment for alcohol addiction. Until then, the medication remains best known for diabetes management and weight loss, even as scientists explore its potential effect on addictive behavior.

“Obviously, if the drug works in veterans, it’s going to work [on] the rest of us that are non-veterans,” Oslin said. “So this is a way to really move the field forward substantially.”

For veterans, the stakes are immediate, given the hundreds of thousands already diagnosed and the strikingly small percentage receiving medication. If this trial confirms earlier findings, primary care clinics could gain a powerful new tool against a disease that has gone undertreated for far too long.

Warning: Account balances and purchasing power no longer tell the same story. Know in 2 minutes if your retirement is working for you.

---

Are you feeling overwhelmed or hopeless right now? Have you been withdrawing from people or activities you usually enjoy? Are you having thoughts about hurting yourself, or feeling like things will never improve?

You do not have to handle those feelings alone. Support is available, and talking to someone can make a difference. You can reach out to the 988 Suicide & Crisis Lifeline by calling or texting 988, or by chatting online at 988lifeline.org. Trained counselors are available 24 hours a day to listen and help.

If you believe someone is in immediate danger, call emergency services right away. Even a small step, like reaching out to a trusted friend, family member, or professional, can help create a path forward.